📊 CDIOW Key Takeaways
Is Cardio Diagnostics Holdings, Inc. (CDIOW) a Good Investment?
Cardio Diagnostics is in critical financial distress with near-zero revenue generation ($14.8K), massive operating losses (-$6.5M), and zero cash reserves despite $7.8M in total assets. The company is burning cash rapidly with negative free cash flow of -$5.9M, indicating it is not operationally viable and faces imminent liquidity crisis without immediate capital infusion.
Cardio Diagnostics shows extremely weak fundamentals: revenue is negligible and declining sharply, while operating and net losses remain several million dollars, producing deeply negative margins and cash flow. The balance sheet has low leverage and reported positive equity, but the absence of cash alongside sustained operating burn raises serious questions about funding durability and the quality of the company’s financial position.
Why Buy Cardio Diagnostics Holdings, Inc. Stock? CDIOW Key Strengths
- Low debt burden with 0.00x debt-to-equity ratio indicating no financial leverage risk
- High current and quick ratios (9.79x) suggest sufficient short-term liquid assets relative to current liabilities
- Modest liabilities of $793.1K represent only 10.1% of total assets
- Low reported liabilities and no meaningful debt reduce balance sheet leverage risk
- Current and quick ratios are high, indicating limited near-term liability pressure on paper
- Positive stockholders’ equity provides some balance sheet cushion relative to liabilities
CDIOW Stock Risks: Cardio Diagnostics Holdings, Inc. Investment Risks
- Revenue collapse of 57.5% YoY with only $14.8K in latest period indicating complete commercial failure
- Zero cash and equivalents with -$5.9M free cash flow burn rate means company has weeks to months of runway remaining
- Net loss of $6.5M per period on negligible revenue results in unsustainable -43,832.5% net margin and -83.7% ROA
- Negative operating cash flow of -$5.7M indicates core business operations are destroying rather than generating value
- Severely diluted shareholder equity with -3.71 diluted EPS and -93.2% ROE showing persistent value destruction
- Revenue base is extremely small and fell 57.5% year over year, suggesting poor commercial traction
- Operating losses and free cash flow burn are severe relative to the size of the business
- Reported cash and equivalents of zero materially increase liquidity and going-concern risk if losses continue
Key Metrics to Watch
- Cash burn rate and remaining runway before insolvency
- Whether company achieves any meaningful revenue growth or secures capital infusion
- Operating expense reduction and path to cash flow breakeven
- Quarterly revenue growth and evidence of sustained commercial adoption
- Cash balance and operating cash burn relative to capital-raising needs
Cardio Diagnostics Holdings, Inc. (CDIOW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.79x current ratio provides a solid financial cushion.
CDIOW Profit Margin, ROE & Profitability Analysis
CDIOW vs Healthcare Sector: How Cardio Diagnostics Holdings, Inc. Compares
How Cardio Diagnostics Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cardio Diagnostics Holdings, Inc. Stock Overvalued? CDIOW Valuation Analysis 2026
Based on fundamental analysis, Cardio Diagnostics Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cardio Diagnostics Holdings, Inc. Balance Sheet: CDIOW Debt, Cash & Liquidity
CDIOW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cardio Diagnostics Holdings, Inc.'s revenue has grown significantly by 3,573% over the 5-year period, indicating strong business expansion. The most recent EPS of $-9.35 indicates the company is currently unprofitable.
CDIOW Revenue Growth, EPS Growth & YoY Performance
CDIOW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.9K | -$1.4M | $-0.98 |
| Q2 2025 | $7.5K | -$1.3M | $-0.97 |
| Q1 2025 | $940 | -$1.6M | $-0.97 |
| Q3 2024 | $6.6K | -$1.4M | $-0.06 |
| Q2 2024 | $1.7K | -$1.3M | $-0.06 |
| Q1 2024 | $15.9K | -$1.0M | $-0.11 |
| Q3 2023 | N/A | -$290.1K | $-0.16 |
| Q2 2023 | N/A | -$290.1K | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cardio Diagnostics Holdings, Inc. Dividends, Buybacks & Capital Allocation
CDIOW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cardio Diagnostics Holdings, Inc. (CIK: 0001870144)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CDIOW
What is the AI rating for CDIOW?
Cardio Diagnostics Holdings, Inc. (CDIOW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CDIOW's key strengths?
Claude: Low debt burden with 0.00x debt-to-equity ratio indicating no financial leverage risk. High current and quick ratios (9.79x) suggest sufficient short-term liquid assets relative to current liabilities. ChatGPT: Low reported liabilities and no meaningful debt reduce balance sheet leverage risk. Current and quick ratios are high, indicating limited near-term liability pressure on paper.
What are the risks of investing in CDIOW?
Claude: Revenue collapse of 57.5% YoY with only $14.8K in latest period indicating complete commercial failure. Zero cash and equivalents with -$5.9M free cash flow burn rate means company has weeks to months of runway remaining. ChatGPT: Revenue base is extremely small and fell 57.5% year over year, suggesting poor commercial traction. Operating losses and free cash flow burn are severe relative to the size of the business.
What is CDIOW's revenue and growth?
Cardio Diagnostics Holdings, Inc. reported revenue of $14.8K.
Does CDIOW pay dividends?
Cardio Diagnostics Holdings, Inc. does not currently pay dividends.
Where can I find CDIOW SEC filings?
Official SEC filings for Cardio Diagnostics Holdings, Inc. (CIK: 0001870144) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CDIOW's EPS?
Cardio Diagnostics Holdings, Inc. has a diluted EPS of $-3.71.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CDIOW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cardio Diagnostics Holdings, Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CDIOW stock overvalued or undervalued?
Valuation metrics for CDIOW: ROE of -93.2% (sector avg: 15%), net margin of -43,832.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CDIOW stock in 2026?
Our dual AI analysis gives Cardio Diagnostics Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CDIOW's free cash flow?
Cardio Diagnostics Holdings, Inc.'s operating cash flow is $-5.7M, with capital expenditures of $187.3K. FCF margin is -39,893.1%.
How does CDIOW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -43,832.5% (avg: 12%), ROE -93.2% (avg: 15%), current ratio 9.79 (avg: 2).